Intuitive Surgical, Inc. $ISRG Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 52,551 shares of the medical equipment provider’s stock after selling 7,689 shares during the quarter. New York Life Investment Management LLC’s holdings in Intuitive Surgical were worth $21,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Bank of America Corp DE boosted its position in Intuitive Surgical by 3.3% in the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after purchasing an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Intuitive Surgical during the 2nd quarter valued at about $1,335,753,000. Amundi grew its stake in shares of Intuitive Surgical by 8.6% during the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after purchasing an additional 193,096 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Intuitive Surgical by 10.8% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,893,485 shares of the medical equipment provider’s stock valued at $769,948,000 after purchasing an additional 184,044 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $450.04 on Wednesday. The stock has a 50-day simple moving average of $413.15 and a two-hundred day simple moving average of $431.20. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88. The firm has a market capitalization of $156.00 billion, a PE ratio of 54.42, a P/E/G ratio of 3.17 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The business had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the prior year, the business posted $2.40 earnings per share. The business’s quarterly revenue was up 21.7% on a year-over-year basis. Equities analysts forecast that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ISRG. Truist Financial lowered their price objective on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Mizuho cut their target price on shares of Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating for the company in a research report on Wednesday, October 21st. Barclays reaffirmed an “overweight” rating and set a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a report on Wednesday, October 21st. Leerink Partners set a $503.00 target price on shares of Intuitive Surgical and gave the company an “outperform” rating in a report on Wednesday, October 21st. Finally, UBS Group reiterated a “buy” rating on shares of Intuitive Surgical in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $493.54.

Insider Activity at Intuitive Surgical

In related news, Director Craig Barratt sold 1,150 shares of the business’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total transaction of $510,370.00. Following the completion of the transaction, the director directly owned 1,150 shares in the company, valued at approximately $510,370. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the completion of the sale, the executive vice president directly owned 881 shares of the company’s stock, valued at $330,877.17. This represents a 8.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,056 shares of company stock worth $17,585,864 in the last quarter. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.